Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 83

Sort by

Sort Order Select

Journal Articles

Genomic Profiles and Subset Characterization of CD8 + terminally Differentiated Effector Memory (T EMRA ) Cells from Cancer Patients

Deok-Hwan Yang, MD PhD, Jae-Sook Ahn, Seo-Yeon Ahn, MD, Sung-Hoon Jung, MD, Je-Jung Lee, MD PhD, Hyeoung-Joon Kim, MD PhD, Young Rok Do, PhDMD, Sang Yun Song, MD PhD, Ga-Young Song, Hyeong Jong Kim, MD, Theresa Kim

Blood (2019) 134 (Supplement_1): 2329.

https://doi.org/10.1182/blood-2019-126533

Published: 2019

Journal Articles

A Combination Therapy with Dendritic Cells, Pomalidomide and Programmed Death-Ligand 1 Blockade Exerts a Potent Antitumor Immunity in a Murine Model of Multiple Myeloma

Je-Jung Lee, MD PhD, Tan-Huy Chu, Manh-Cuong Vo, Hye-Sung Park, Thangaraj Jaya Lakshmi, Seo-Yeon Ahn, MD, Ga-Young Song, Sung-Hoon Jung, MD, Hyeoung-Joon Kim, MD PhD

Blood (2019) 134 (Supplement_1): 1819.

https://doi.org/10.1182/blood-2019-127964

Published: 2019

Journal Articles

Long-Term Outcomes of Chronic Myeloid Leukemia Patients Who Lost Undetectable Molecular Residual Disease (UMRD) after Imatinib Discontinuation: Korean Imatinib Discontinuation Study (KIDS)

Sung-Eun Lee, MD, Joon Seong Park, MD, Hyeoung-Joon Kim, MD PhD, Sung-Hyun Kim, MD PhD, Dae Young Zang, MD PhD, Sukjoong Oh, MD PhD, Young Rok Do, PhDMD, Yunsuk Choi, MD, Jae-Yong Kwak, MD PhD, Jeong-A Kim, MD PhD, Kyoo Hyung Lee, MD PhD, Yeung-Chul Mun, MD, Won Sik Lee, MD PhD, Myung Hee Chang, MD, Jinny Park, MD PhD, Jihyun Kwon, MD, Dong-Wook Kim

Blood (2019) 134 (Supplement_1): 1643.

https://doi.org/10.1182/blood-2019-126376

Published: 2019

Journal Articles

Clinical Impact of Enrollment of Clinical Trial in Multiple Myeloma; Single Center Experience

Seo-Yeon Ahn, MD, Sung-Hoon Jung, MD, Ga-Young Song, Deok-Hwan Yang, MD PhD, Jae-Sook Ahn, MD PhD, Hyeoung-Joon Kim, MD PhD, Je-Jung Lee, MD PhD

Blood (2019) 134 (Supplement_1): 5525.

https://doi.org/10.1182/blood-2019-127889

Published: 2019

Journal Articles

High Residual Allelic Burden Increases Leukemic Transformation Irrespective of Clinical Response in Patients with Lower Risk Myelodysplastic Syndrome Treated with Azacitidine

Joon Ho Moon, MD, Hee Jeong Cho, MD, Dong Won Baek, MD, Sang Kyun Sohn, MD PhD, Jae-Sook Ahn, Seo-Yeon Ahn, MD, Seunghyun Choi, PhD, Kyoung Ha Kim, MD PhD, Taehyung Kim, Zhaolei Zhang, PhD, Hyeoung-Joon Kim, MD PhD, Dennis Dong Hwan Kim, MD PhD

Blood (2019) 134 (Supplement_1): 4263.

https://doi.org/10.1182/blood-2019-130428

Published: 2019

Journal Articles

18 f-FDG PET/CT and the Revised International Staging System Are More Discriminating of Survival Outcomes in Newly Diagnosed Multiple Myeloma

Sung-Hoon Jung, MD, Seong Young Kwon, Jung-Joon Min, Hee Seung Bom, Seo-Yeon Ahn, MD, Seung-Yeon Jung, Seung-Shin Lee, MD, Moo-Rim Park, MD, Deok-Hwan Yang, MD, Jae-Sook Ahn, MD PhD, Hyeoung-Joon Kim, MD PhD, Je-Jung Lee, MD PhD

Blood (2018) 132 (Supplement 1): 4483.

https://doi.org/10.1182/blood-2018-99-112354

Published: 2018

Journal Articles

Identification of High Risk Group for Leukemic Transformation in Higher Risk MDS Patients Using Targeted RNA-Sequencing: Hematopoietic Stem Cell Signature As a High Risk Profile for Leukemic Transformation

Joon Ho Moon, MD, Taehyung Kim, MSc, Jae-Sook Ahn, MD PhD, Seo-Yeon Ahn, MD, Sung-Hoon Jung, MD, Deok-Hwan Yang, MD, Je-Jung Lee, MD PhD, Seunghyun Choi, PhD, Yoojin Lee, MD PhD, Sang Kyun Sohn, MD PhD, Hyeoung-Joon Kim, MD PhD, Zhaolei Zhang, PhD, Dennis Dong Hwan Kim, MD PhD

Blood (2018) 132 (Supplement 1): 4361.

https://doi.org/10.1182/blood-2018-99-116241

Published: 2018

Journal Articles

Diagnostic Accuracy of Immunoglobulin Heavy Chain Rearrangement, FDG-PET/CT and Unilateral Bone Marrow Trephination for Detecting Bone Marrow Involvement in Diffuse Large B Cell Lymphoma

Seung-Yeon Jung, Sung-Hoon Jung, MD, Seo-Yeon Ahn, MD, Je-Jung Lee, MD PhD, Hyeoung-Joon Kim, MD PhD, Jun Hyung Lee, MD, Myung Geun Shin, MD PhD, Su Woong Yoo, Deok-Hwan Yang, MD PhD

Blood (2018) 132 (Supplement 1): 4236.

https://doi.org/10.1182/blood-2018-99-116398

Published: 2018

Journal Articles

Prognostic Significance of FDG-PET/CT on Determining Upfront Autologous Stem Cell Transplantation for the Treatment of Peripheral T Cell Lymphomas

Seo-Yeon Ahn, MD, Seung-Yeon Jung, Sung-Hoon Jung, MD, Jae-Sook Ahn, MD PhD, Je-Jung Lee, MD PhD, Hyeoung-Joon Kim, MD PhD, Sae-Ryung Kang, MD, Yeon-Hee Han, MD, Jae-Yong Kwak, MD PhD, Ho-Young Yhim, MD PhD, Deok-Hwan Yang, MD PhD

Blood (2018) 132 (Supplement 1): 1632.

https://doi.org/10.1182/blood-2018-99-118168

Published: 2018

Journal Articles

Final Study Results of Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 48 Months Follow-up

Blood (2018) 132 (Supplement 1): 1733.

https://doi.org/10.1182/blood-2018-99-110568

Published: 2018

Journal Articles

Allogeneic Hematopoietic Cell Transplantation for Severe Idiopathic Aplastic Anemia Older Than 40y

Hawk Kim, MD PhD, Yunsuk Choi, MD, Sung-Soo Yoon, MD PhD, Soo-Mee Bang, MD PhD, Hyeoung-Joon Kim, MD PhD, Sang Kyun Sohn, MD PhD, Yeung-Chul Mun, Young Rok Do, PhD MD, Yong Park, MD, Ji Hyun Lee, MD PhD, Sung Hwa Bae, MD, Ho Sup Lee, MD, Min Kyoung Kim, MD PhD, Won-Sik Lee, Jeong-Yeal Ahn, MD, Kyoo-Hyung Lee, MD PhD

Blood (2018) 132 (Supplement 1): 3876.

https://doi.org/10.1182/blood-2018-99-116190

Published: 2018

Journal Articles

RNA Sequencing-Based Measurement of Fusion-Transcript for Minimal Residual Disease (MRD) Monitoring in Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)

Taehyung Kim, MSc, Joon Ho Moon, MD, Jae-Sook Ahn, MD PhD, Marc S. Tyndel, B. Eng, Seung-Shin Lee, MD, Seo-Yeon Ahn, MD, Sung-Hoon Jung, MD, Deok-Hwan Yang, MD PhD, Je-Jung Lee, MD PhD, Seunghyun Choi, PhD, Ja-yeon Lee, MSc, Yoojin Lee, MDPhD, Sang Kyun Sohn, MD PhD, Zhaolei Zhang, PhD, Hyeoung-Joon Kim, MD PhD, Dennis Dong Hwan Kim, MD PhD

Blood (2018) 132 (Supplement 1): 2669.

https://doi.org/10.1182/blood-2018-99-112037

Published: 2018

Journal Articles

Residual Allelic Burden Measured By Next-Generation Sequencing (NGS) at Remission Provides Limited Prognostic Value to Predict Relapse and Long-Term Outcome in Core Binding Factor Acute Myeloid Leukemia (CBF-AML)

Taehyung Kim, MSc, Joon Ho Moon, MD, Jae-Sook Ahn, MD PhD, Marc S. Tyndel, B. Eng, Seung-Shin Lee, MD, Seo-Yeon Ahn, MD, Sung-Hoon Jung, MD, Deok-Hwan Yang, MD, Je-Jung Lee, MD PhD, Seunghyun Choi, PhD, Ja-yeon Lee, MSc, Yoojin Lee, MDPhD, Sang Kyun Sohn, MDPhD, Hyeoung-Joon Kim, MD PhD, Zhaolei Zhang, PhD, Dennis Dong Hwan Kim, MD PhD

Blood (2018) 132 (Supplement 1): 1391.

https://doi.org/10.1182/blood-2018-99-112906

Published: 2018

Journal Articles

Enhancement of Antitumor Immunity Using Dendritic Cells Combined with Lenalidomide and Programmed Death Ligand-1 Blockade in Multiple Myeloma Mouse Model

Je-Jung Lee, MD PhD, Manh-Cuong Vo, Sung-Hoon Jung, MD, Tan-Huy Chu, Hyun-Ju Lee, Thangaraj Jaya Lakshmi, Hyeoung-Joon Kim, MD PhD

Blood (2018) 132 (Supplement 1): 3194.

https://doi.org/10.1182/blood-2018-99-112359

Published: 2018

Journal Articles

RUNX1 Mutation in Cytogenetically Normal Acute Myeloid Leukemia : Clinical Implications, Co-Mutation Analysis

Blood (2016) 128 (22): 5253.

https://doi.org/10.1182/blood.V128.22.5253.5253

Published: 2016

Journal Articles

Longitudinal Tracking of MDS Patients Using Next Generation Sequencing Provides a Predictive Measure for Azacitidine Response and AML Progression

Blood (2016) 128 (22): 52.

https://doi.org/10.1182/blood.V128.22.52.52

Published: 2016

Journal Articles

Killer Cell Immunoglobulin-like Receptor Ligand Matching Determines the Post-Transplant High Risk Groups Among Patients with Permissive HLA Mismatch in Unrelated Donor Hematopoietic Cell Transplantation

Yoo Jin Lee, MD, Joon Ho Moon, MD, PhD, In Hee Lee, MD, Jae-Ho Yoon, Byung-Sik Cho, Jae-Sook Ahn, MD PhD, Hyeoung Joon Kim, MD PhD, Silvia Park, Jun Ho Jang, MD PhD, Chul Won Jung, MD PhD, Hyunsung Park, MD, June-Won Cheong, MD, Je-Hwan Lee, MD PhD, Sang Kyun Sohn, MD, PhD, Hee-Je Kim

Blood (2016) 128 (22): 4566.

https://doi.org/10.1182/blood.V128.22.4566.4566

Published: 2016

Journal Articles

Genome-Wide Genotype-Based Risk Model for Survival in Core Binding Factor Acute Myeloid Leukemia Patients

Silvia Park, Choi Hangseok, Hee-Je Kim, Jae-Sook Ahn, Hyeoung Joon Kim, MD PhD, Sung-Hyun Kim, Yeung-Chul Mun, Chul Won Jung, MD PhD, Dong Hwan Kim, MD PhD

Blood (2016) 128 (22): 1623.

https://doi.org/10.1182/blood.V128.22.1623.1623

Published: 2016

Journal Articles

Whole Exome Sequencing Reveals the Landscape of Clonal Evolution from MDS to AML Progression

Taehyung Simon Kim, PhD, Zhaolei Zhang, PhD, Marc Tyndel, Jae-Sook Ahn, MDPhD, Yeo-Kyeoung Kim, MD, PhD, Seung Hyun Choi, PhD, Hyeoung-Joon Kim, MD PhD, Moses Lee, Murim Choi, Jeffrey H. Lipton, MD PhD, Dennis Dong Hwan Kim, MD PhD

Blood (2015) 126 (23): 2596.

https://doi.org/10.1182/blood.V126.23.2596.2596

Published: 2015

Journal Articles

5-Hydroxymethylcytosine Is Correlated with TET2 or IDH1/2 Mutations However, May Not be a Prognostic Value to Predict the Survivals in Normal Karyotype AML

Jae-Sook Ahn, MDPhD, Hyeoung-Joon Kim, MD PhD, Yeo-Kyeoung Kim, MD, PhD, Seung-Shin Lee, MD, Sung-Hoon Jung, MD PhD, Deok-Hwan Yang, MD PhD, Je-Jung Lee, Park Hee Jeong, Seung Hyun Choi, PhD, Chul Won Jung, MD PhD, Jun-Ho Jang, MD PhD, Heeje Kim, MD PhD, Joon Ho Moon, MD, PhD, Sang Kyun Sohn, MD PhD, Sung-Hyun Kim, Dennis Dong Hwan Kim, MD PhD

Blood (2015) 126 (23): 3832.

https://doi.org/10.1182/blood.V126.23.3832.3832

Published: 2015

NARROW

Genomic Profiles and Subset Characterization of CD8 + terminally Differentiated Effector Memory (T EMRA ) Cells from Cancer Patients

A Combination Therapy with Dendritic Cells, Pomalidomide and Programmed Death-Ligand 1 Blockade Exerts a Potent Antitumor Immunity in a Murine Model of Multiple Myeloma

Long-Term Outcomes of Chronic Myeloid Leukemia Patients Who Lost Undetectable Molecular Residual Disease (UMRD) after Imatinib Discontinuation: Korean Imatinib Discontinuation Study (KIDS)

Clinical Impact of Enrollment of Clinical Trial in Multiple Myeloma; Single Center Experience

High Residual Allelic Burden Increases Leukemic Transformation Irrespective of Clinical Response in Patients with Lower Risk Myelodysplastic Syndrome Treated with Azacitidine

18 f-FDG PET/CT and the Revised International Staging System Are More Discriminating of Survival Outcomes in Newly Diagnosed Multiple Myeloma

Identification of High Risk Group for Leukemic Transformation in Higher Risk MDS Patients Using Targeted RNA-Sequencing: Hematopoietic Stem Cell Signature As a High Risk Profile for Leukemic Transformation

Diagnostic Accuracy of Immunoglobulin Heavy Chain Rearrangement, FDG-PET/CT and Unilateral Bone Marrow Trephination for Detecting Bone Marrow Involvement in Diffuse Large B Cell Lymphoma

Prognostic Significance of FDG-PET/CT on Determining Upfront Autologous Stem Cell Transplantation for the Treatment of Peripheral T Cell Lymphomas

Final Study Results of Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase (CML-CP) Patients Receiving Radotinib 300 Mg BID or Imatinib: Rerise 48 Months Follow-up

Allogeneic Hematopoietic Cell Transplantation for Severe Idiopathic Aplastic Anemia Older Than 40y

RNA Sequencing-Based Measurement of Fusion-Transcript for Minimal Residual Disease (MRD) Monitoring in Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)

Residual Allelic Burden Measured By Next-Generation Sequencing (NGS) at Remission Provides Limited Prognostic Value to Predict Relapse and Long-Term Outcome in Core Binding Factor Acute Myeloid Leukemia (CBF-AML)

Enhancement of Antitumor Immunity Using Dendritic Cells Combined with Lenalidomide and Programmed Death Ligand-1 Blockade in Multiple Myeloma Mouse Model

RUNX1 Mutation in Cytogenetically Normal Acute Myeloid Leukemia : Clinical Implications, Co-Mutation Analysis

Longitudinal Tracking of MDS Patients Using Next Generation Sequencing Provides a Predictive Measure for Azacitidine Response and AML Progression

Killer Cell Immunoglobulin-like Receptor Ligand Matching Determines the Post-Transplant High Risk Groups Among Patients with Permissive HLA Mismatch in Unrelated Donor Hematopoietic Cell Transplantation

Genome-Wide Genotype-Based Risk Model for Survival in Core Binding Factor Acute Myeloid Leukemia Patients

Whole Exome Sequencing Reveals the Landscape of Clonal Evolution from MDS to AML Progression

5-Hydroxymethylcytosine Is Correlated with TET2 or IDH1/2 Mutations However, May Not be a Prognostic Value to Predict the Survivals in Normal Karyotype AML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only